Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.59 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3440191 | 0.98 | ESR1 (0.57) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL13108706 | 0.91 | DGAT1 (0.62) | ESR1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL20766398 | 0.89 | DGAT1 (0.60) | ESR1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL17512889 | 0.89 | DGAT1 (0.60) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL13108731 | 0.84 | DGAT1 (0.56) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL10040530 | 0.84 | DGAT1 (0.56) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL15294298 | 0.83 | DGAT1 (0.55) | ESR1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL2327193 | 0.83 | DGAT1 (0.55) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL2828698 | 0.81 | DGAT1 (0.53) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL15650610 | 0.81 | CYP3A4 (0.60) | ESR1ESR2DGAT1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019009369-A1 | IMINE DERIVATIVE | 大日本住友製薬株式会社 | 2019-01-10 | — | — | WO | disclosed |
| EP-1622866-B1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-7825260-B2 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7807841-B2 | Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors | IRM LLC (BM) | 2010-10-05 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090124597-A1 | SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-05-14 | — | — | US | disclosed |
| CN-101420959-A | Use of 2- (purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives as adenosine A2A receptor agonists | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| CN-101128473-A | Adenosine derivatives having a2a receptor activity | NOVARTIS AG (CH) | 2008-02-20 | — | — | CN | disclosed |
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1622866-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096757-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-5488160-A | LEUKOTRIENE B4 RECEPTOR ANTAGONIST AS ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| US-5451700-A | Leukotriene inhibitors | CIBA-GEIGY CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0518819-B1 | Amidino compounds, their manufacture and use as medicament | CIBA GEIGY AG (CH) | 1995-08-02 | — | — | EP | disclosed |
| US-5246965-A | Leukotriene antagonist | CIBA-GEIGY (US) | 1993-09-21 | — | — | US | disclosed |
| EP-0518818-A2 | Arylethers, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
| EP-0518819-A2 | Amidino compounds, their manufacture and use as medicament | CIBA-GEIGY AG (CH) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | S1PR1, S1PR3, S1PR2 | ESR1 989/4885CA12 4864/4885CA1 4793/4885 |
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ESR1 384/4885CA12 3122/4885CA1 2903/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ESR1 271/4885CA12 1962/4885CA1 3554/4885 |
| US-20090124597-A1 | SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR3C2, NR5A1, ESRRA | ESR1 67/4885CA12 3230/4885CA1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.